e-ISSN: Pending
Negative / Null Result ReportOpen accessDiseases of the endocrine glands. Clinical endocrinology

Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study

Takehiro Sugiyama; Takashi Furuno; Yuichi Ichinose; Masao Iwagami; Noriko Ihana‐Sugiyama; Kenjiro Imai; Tamaki Kakuwa; Ryoko Rikitake · 2024 · Journal of Diabetes Investigation

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

ABSTRACT Aims/Introduction A recent US Food and Drug Administration report highlighted concerns over nitrosamine (7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine [NTTP]) impurities in sitagliptin, prompting investigations into its safety profile. The present study aimed to determine if the use of NTTP‐contaminated sitagliptin, in comparison with other dipeptidyl peptidase‐4 (DPP‐4) inhibitors, is associated with an increased cancer risk. Materials and Methods This retrospective cohort study secondarily used the National Database of Health Insurance Claims and S

Abstract by Takehiro Sugiyama; Takashi Furuno; Yuichi Ichinose; Masao Iwagami; Noriko Ihana‐Sugiyama; Kenjiro Imai; Tamaki Kakuwa; Ryoko Rikitake, Journal of Diabetes Investigation (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.1111/jdi.14281